Clinical development of cancer therapeutics that target metabolism

B. F. Clem, J. O'Neal, A. C. Klarer, S. Telang, J. Chesney

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Glucose and glutamine metabolismin cancer cells are markedly elevated relative to non-transformed normal cells. This metabolic reprogramming enables the production of adenosine triphosphate and the anabolic precursors needed for survival, growth and motility. The recent observations that mutant oncogenic proteins and the loss of tumor suppressors activate key metabolic enzymes suggest that selective inhibition of these enzymes may yield effective cancer therapeutics with acceptable toxicities. In support of this concept, pre-clinical studies of small molecule antagonists of several metabolic enzymes in tumor-bearing mice have demonstrated reasonable therapeutic indices. We will review the rationale for targeting metabolic enzymes as a strategy to treat cancer and will detail the results of several recent clinical trials of metabolic inhibitors in advanced cancer patients.

Original languageEnglish
Pages (from-to)367-372
Number of pages6
Issue number6
StatePublished - Jun 2016


Dive into the research topics of 'Clinical development of cancer therapeutics that target metabolism'. Together they form a unique fingerprint.

Cite this